Evaluating the cost effectiveness of the addition 2011 RAFIA.pdf (107.38 kB)
Download fileEvaluating the cost-effectiveness of the addition of rituximab to chemotherapy in the first-line treatment of Follicular Lymphoma patients in the UK
poster
posted on 2020-02-25, 10:35 authored by Rachid Rafia, Diana PapaioannouDiana Papaioannou, Matthew StevensonMatthew Stevenson, J. Rathbone, Helen Buckley WoodsINTRODUCTION
Follicular lymphoma (FL), a clinical subtype of Non-Hodgkin’s lymphoma (NHL) , develops
slowly and often without symptoms for many years. In 2008, the incidence of FL in England
and Wales was 3.4 per 100,000 persons. Over 70% of FLs are diagnosed in persons aged
over 60 years, and 85-90% present with advanced disease, which is defined as lymph nodes
on both sides of the diaphragm being involved (stage III) or disease is disseminated with one
or more extra-lymphatic organs involved (stage IV). Advanced FL is not curable, thus the aim
of disease management is to both increase patient life expectancy and to increase patient
health-related quality of life. The objective of this study is to assess, from a UK NHS
perspective, the cost-effectiveness of the addition of rituximab (R) to selected
chemotherapies: CVP (cyclophosphamide, vincristine and prednisolone); CHOP
(cyclophosphamide, doxorubicin, vincristine and prednisolone) and MCP (mitoxantrone,
chlorambucil and prednisolone) in the first-line treatment of follicular lymphoma.
History
Ethics
- There is no personal data or any that requires ethical approval
Policy
- The data complies with the institution and funders' policies on access and sharing
Sharing and access restrictions
- The data can be shared openly
Data description
- The file formats are open or commonly used
Methodology, headings and units
- Headings and units are explained in the files